Top Biomed Stock
Report Date: 12-18-2023
Symbol: IBRX - ImmunityBio, Inc.
Sector:
Industry:
Top Biomed Stock Signal: IBRX
ImmunityBio, Inc. (IBRX)
2040 E MARIPOSA AVENUE
El Segundo, CA 92121
Phone: 310 883 1300
Website: http://immunitybio.com
CEO: Dr. Patrick Soon-Shiong F.A.C.S., M.Sc., FRCS (C), M.D., FACS
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.